- Home
- CYRX vs NGNE Comparison
CYRX vs NGNE Comparison
Compare CYRX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- NGNE
- Stock Information
- Founded
- CYRX 1999
- NGNE 2003
- Country
- CYRX United States
- NGNE United States
- Employees
- CYRX N/A
- NGNE N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- NGNE Health Care
- Exchange
- CYRX Nasdaq
- NGNE Nasdaq
- Market Cap
- CYRX 438.7M
- NGNE 426.6M
- IPO Year
- CYRX N/A
- NGNE N/A
- Fundamental
- Price
- CYRX $8.80
- NGNE $20.10
- Analyst Decision
- CYRX Strong Buy
- NGNE Strong Buy
- Analyst Count
- CYRX 9
- NGNE 6
- Target Price
- CYRX $12.83
- NGNE $38.50
- AVG Volume (30 Days)
- CYRX 722.5K
- NGNE 291.5K
- Earning Date
- CYRX 11-04-2025
- NGNE 11-13-2025
- Dividend Yield
- CYRX N/A
- NGNE N/A
- EPS Growth
- CYRX N/A
- NGNE N/A
- EPS
- CYRX 1.27
- NGNE N/A
- Revenue
- CYRX $243,795,000.00
- NGNE N/A
- Revenue This Year
- CYRX N/A
- NGNE N/A
- Revenue Next Year
- CYRX $9.20
- NGNE N/A
- P/E Ratio
- CYRX $6.95
- NGNE N/A
- Revenue Growth
- CYRX 41.27
- NGNE N/A
- 52 Week Low
- CYRX $4.58
- NGNE $6.88
- 52 Week High
- CYRX $11.44
- NGNE $37.27
- Technical
- Relative Strength Index (RSI)
- CYRX 46.95
- NGNE 34.27
- Support Level
- CYRX $8.15
- NGNE $19.68
- Resistance Level
- CYRX $9.29
- NGNE $22.42
- Average True Range (ATR)
- CYRX 0.49
- NGNE 2.81
- MACD
- CYRX -0.02
- NGNE -1.29
- Stochastic Oscillator
- CYRX 43.54
- NGNE 2.93
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.